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Aging is associated with changes to the immune system, collectively termed
immunosenescence and inflammageing. However, the relationships among age, frailty,
and immune parameters in older people resident in care homes are not well described. We
assessed immune and inflammatory parameters in 184 United Kingdom care home
residents aged over 65 years and how they relate to age, frailty index, and length of
care home residence. Linear regression was used to identify the independent contribution
of age, frailty, and length of care home residence to the various immune parameters as
dependent variables. Participants had a mean age (±SD) of 85.3 ± 7.5 years, had been
residing in the care home for a mean (±SD) of 1.9 ± 2.2 years at the time of study
commencement, and 40.7% were severely frail. Length of care home residence and frailty
index were correlated but age and frailty index and age and length of care home residence
were not significantly correlated. All components of the full blood count, apart from total
lymphocytes, were within the reference range; 31% of participants had blood lymphocyte
numbers below the lower value of the reference range. Among the components of the full
blood count, platelet numbers were positively associated with frailty index. Amongst
plasma inflammatory markers, C-reactive protein (CRP), interleukin-1 receptor antagonist
(IL-1ra), soluble E-selectin and interferon gamma-induced protein 10 (IP-10) were
positively associated with frailty. Plasma soluble vascular cell adhesion molecule 1
(sVCAM-1), IP-10 and tumor necrosis factor receptor II (TNFRII) were positively
associated with age. Plasma monocyte chemoattractant protein 1 was positively
associated with length of care home residence. Frailty was an independent predictor
of platelet numbers, plasma CRP, IL-1ra, IP-10, and sE-selectin. Age was an independent
predictor of activated monocytes and plasma IP-10, TNFRII and sVCAM-1. Length of care
home residence was an independent predictor of plasma MCP-1. This study concludes
that there are independent links between increased frailty and inflammation and between
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increased age and inflammation amongst older people resident in care homes in the
United Kingdom. Since, inflammation is known to contribute to morbidity and mortality in
older people, the causes and consequences of inflammation in this population should be
further explored.
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INTRODUCTION
The number and proportion of older people is increasing in many
societies (GBD 2016 Causes of Death Collaborators, 2017; GBD
2016 DALYs and HALE Collaborators, 2017). Aging increases the
risk of morbidity, bringing with it loss of independence, increased
health and social care costs, and for many older people, the need
to move to a care home. Aging is also associated with changes to
the immune system, collectively termed immunosenescence (De
Martinis et al., 2004; Agarwal and Busse, 2010; Pawelec et al.,
2010; Castelo-Branco and Soveral, 2014; Bektas et al., 2017) and
inflammageing (Franceschi, 2007; Calder et al., 2017; Ventura
et al., 2017; Atienza et al., 2018). Immunosenescence involves
changes in the numbers of different immune cells in the
bloodstream and reductions in their function (De Martinis
et al., 2004; Agarwal and Busse, 2010; Pawelec et al., 2010;
Castelo-Branco and Soveral, 2014; Bektas et al., 2017). For
example, there is reduced production and export of naïve T
lymphocytes into the blood (and lymphoid tissues) during
aging with a loss in T cell receptor diversity and an
accumulation of memory T lymphocytes (Agarwal and Busse,
2010; Pawelec et al., 2010; Castelo-Branco and Soveral, 2014;
Bektas et al., 2017). The overall result of these changes are lowered
numbers of T lymphocytes in the blood and impaired T
lymphocyte responsiveness (De Martinis et al., 2004; Agarwal
and Busse, 2010; Pawelec et al., 2010; Castelo-Branco and Soveral,
2014; Bektas et al., 2017). Immunosenescence also affects B
lymphocyte numbers and function and the function of antigen
presenting cells and some components of innate immunity (De
Martinis et al., 2004; Agarwal and Busse, 2010; Pawelec et al.,
2010; Castelo-Branco and Soveral, 2014; Bektas et al., 2017).
Inflammageing is seen as an increase in blood plasma or serum
concentrations of the acute phase protein C-reactive protein
(CRP) and of inflammatory cytokines like interleukin (IL)-6
(Franceschi, 2007; Calder et al., 2017; Ventura et al., 2017;
Atienza et al., 2018). This may reflect sensitized pro-
inflammatory signaling pathways in older people. Together
these changes contribute to the increased prevalence and
severity of infections (Yoshikawa, 2000; Pera et al., 2015), the
poorer responses to vaccinations (Goodwin et al., 2006;
Trzonkowski et al., 2009; Derhovanessian and Pawelec, 2012)
and the increased likelihood to suffer illness and disability (Onder
et al., 2012) that occur with aging. However, aging is
heterogeneous and occurs at different rates in different
individuals; different settings may influence the aging process,
for example by providing different access to a good diet, physical
activity, mental stimulation and social interactions. It is described
that free-living older individuals have a significantly better quality
of life when compared with older people in institutional care
homes (Montoya and Mody, 2011; Olsen et al., 2016; Sampson
et al., 2019). This may relate to the different experiences offered
outside and inside care homes which may themselves contribute
to the aging process.
Frailty is currently recognized as a ”geriatric syndrome”
(Laksmi, 2014; Chen et al., 2016). Categorization of frailty has
traditionally been according to physical mobility and strength
(Dent et al., 2016), although there is also a cognitive component
to frailty as recognized in some scales for evaluating the extent of
frailty among older people (Morley et al., 2013). Frail older adults
are at increased risk of adverse health outcomes, including falls,
hospitalization, and mortality (Beck-Sague et al., 1994; Ahmed
et al., 2007). It has been suggested that one of the important
pathways of frailty development is the immune/inflammatory
pathway (Wilson et al., 2017). Inflammation has also been linked
to a wide range of chronic diseases of common prevalence within
older populations (Franceschi, 2007; Bauer and Fuente, 2016).
Age, frailty, and length of care home residence might be linked to
adverse outcomes (Carneiro et al., 2017). In order to better
understand the relationships of age, frailty and length of care
home residence with immunosenescence and inflammageing, we
measured a range of immune and inflammatory markers in 184
United Kingdom care home residents aged over 65 years and
investigated the relevant associations. We assessed static
measures in blood (full blood count, immune phenotypes,
plasma immune mediator concentrations, plasma CRP) as well
as blood immune cell responses after ex vivo challenge
(phagocytosis, blood culture responses to immune stimulation)
and included components of both innate and acquired immunity.
Many of these markers have not been well explored in the context
of aging or frailty or in older people in the care home setting.
METHODS
Participants
This cross-sectional study is embedded within the “Probiotics to
reduce infections in care home residents” (PRINCESS) trial
which is a two-arm double-blind individually randomized
controlled trial, involving three academic centers in the
United Kingdom (Universities of Cardiff, Oxford and
Southampton). The full protocol (Owen-Jones et al., 2019) and
the main outcomes (Butler et al., 2020) of the PRINCESS trial
have been published. The PRINCESS trial was approved by the
Wales REC 3 (15/WA/0306) and is registered at www.controlled-
trials.com as ISRCTN16392920. Care home residents were
eligible for participation if they were aged 65 years or older
and willing and able to give informed consent for
participation; if they lacked capacity, a consultee could
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complete a consultee declaration for participation on their behalf.
Exclusions were immunocompromize (ongoing immune-
suppressants; long-term, high-dose, oral, intramuscular or
intravenous steroids), lactose intolerance, taking ongoing
regular probiotics, or temporary residence in the care home.
Care homes were residential, nursing or mixed. Here we report
frailty and immune parameters in a subset of participants whose
data was available at study entry (n  184, although not all
immune parameters were available for all these participants).
Data were not available for all participants in themain PRINCESS
trial and in this sub-study because 1) participants did not consent
to take part in the immune sub-study of PRINCESS; or 2)
insufficient blood was collected to measure some or any of the
immune parameters; or 3) the blood arrived at the University of
Southampton, where immune measurements were made, outside
of a time window pre-determined based upon an earlier study
(Castro-Herrera et al., 2018).
Assessment of Frailty
Frailty index was determined according to the scale described
elsewhere (Morley et al., 2013). The scale has nine categories
defined as: 1  Very fit for their age (active, energetic and
motivated); 2  Well (absent symptomatology of disease but
less active); 3  Managing well (medical problems under control
but not regularly active); 4  Vulnerable (symptoms that limit
activities but not decedent on others); 5  Mildly frail
(impairment of daily activities); 6  Moderately frail
(progressive impairment and declined activities); 7  Severely
frail (completely dependent cognitively or physically but not
terminally ill); 8  Very severely frail (completely dependent
and approaching the end of life); 9  Terminally ill (life
expectancy < 6 months).
Measurement of Immune Parameters
Blood was collected into EDTA or heparin at the care homes and
was posted to the University of Southampton. Whole blood was
used to determine full blood count, for immune phenotyping, for
assessment of neutrophil and monocyte phagocytosis, and for
cultures to determine production of immune mediators after
stimulation. Plasma was prepared for measurement of CRP and
immune mediator concentrations. Immune parameters were
measured as described in detail previously (Castro-Herrera
et al., 2018). Briefly, full blood count was determined in blood
collected into EDTA using an automated UniCel Beckman
Coulter Dxl 800 (Beckman Coulter, High Wycombe,
United Kingdom). Full blood collected into heparin was used
for immune phenotyping using flow cytometry following staining
with fluorescently labelled antibodies to immune cell surface
structures. Blood (500 µl) was placed in BD Trucount™ tubes
(BD Pharmingen Oxford, United Kingdom). Antibodies were
purchased from BD Pharmingen (Oxford, United Kingdom).
Table 1 lists the details of the immune phenotyping. Staining
was performed at room temperature for 20 min and protected
from light. BD-FACS lysing solution (1 ml; BD Pharmingen
Oxford, United Kingdom) was added and tubes were
incubated for 20 min. Tubes were vortexed and placed at
room temperature in a dark place. Tubes were analyzed on a
BD FACS LSRF Fortessa TM X-20 Special order (BD Biosciences,
San Jose, CA). Isotype controls were run at a medium flow rate.
10,000 events were collected for all samples in tubes containing
Trucount beads. Beads were gated and 5,000 events were collected
within the bead region. Data analyses were performed with BD
FACSDiva 8.0.1 software. Instrument stability was checked daily
using the cytometer setup and tracking to evaluate performance
with Research Beads™ (BD Biosciences, Oxford,
United Kingdom).
Phagocytic activity of blood neutrophils and monocytes
toward E. coli was assessed in heparinsed whole blood (200 µl)
using the commercially available Phagotest™ kit (Glycotope
Biotechnology GmbH, Heidelberg Germany). Events (20,000)
were collected using a BD FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA). Both the percentage of cells
(neutrophils and monocytes) involved in phagocytosis and
their geometric mean fluorescence intensity (reflecting the
number of ingested bacteria per cell) were analyzed.
For whole blood cultures, 500 μl heparinized whole blood was
diluted 1:10 in Roswell Park Memorial Institute 1640 culture
medium supplemented with penicillin (50 U/ml), streptomycin
(50 μg/ml) and L-glutamine (2 mM) (Sigma Aldrich, Gillingham,
United Kingdom). Diluted blood (990 μl) was added to the wells
of a 24-well flat-bottomed cell culture plate. Then, 10 µl of either
medium, lipopolysaccharide (LPS; from E. coli K12 strain),
peptidoglycan (PGN; from Staphylococcus aureus) or
phytohaemagglutinin (PHA; from Phaseolus vulgaris) was
added to the wells to obtain final concentrations of 10 μg/ml
LPS, 5 μg/ml PGN or 5 μg/ml PHA respectively. Cultures were
incubated for 24 h at 37°C in an atmosphere of 95% air and 5%
CO2. Supernatants were collected by centrifuging the plate at
2000 rpm for 5 min and were then stored at −80°C for analysis.
Once all supernatants were ready to be analyzed, magnetic
luminex assays (Bio-Techne, R&D Systems, Abingdon,
United Kingdom) were used. Analytes were measured in
negative controls and in the medium after stimulation with
PGN or LPS and the assay limits of detection (pg/ml) were:
tumor necrosis factor (TNF-α) (0.62), interleukin (IL)-1β (0.25),
IL-6 (0.38), IL-10 (2.93), and IL-12p70 (2.39). Analytes measured
following stimulation with PHA were TNF-α (limit of detection
(pg/ml) (1.2) and interferon (IFN-γ) (0.4). Assays were
performed according to manufacturer’s instructions.
Microparticles were resuspended in buffer and read using a
Bio-Rad-plex Luminex Analyzer.
Plasma was prepared from 1 ml of heparinized whole blood by
centrifugation at 1,500 rpm for 5 min and stored at −20°C prior to
analysis. CRP, immune mediators and soluble receptors were
measured by magnetic luminex assays (Bio-Techne, R&D
Systems, Abingdon, United Kingdom). Analytes measured and
the assay limits of detection (pg/ml) were CRP (116), TNF-α
(0.54), IL-6 (0.31), IL-10 (0.24), IL-17 (1.8), IL-12p70 (2.96), IL-
1ra (18), TNF receptor II (TNFRII; 0.5), monocyte chemoattract
protein (MCP-1; 9.9), soluble vascular cell adhesion molecule
(sVCAM-1; 238), soluble E-selectin (sE-selectin; 18.8), soluble
intercellular adhesion molecule (sICAM-1; 87.9), and interferon
gamma-induced protein 10 (IP-10; 1.18). Assays were performed
according to manufacturer’s instructions. Microparticles were
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resuspended in buffer and read using a Bio-Rad-plex Luminex
Analyzer.
Statistical Analysis
As this is an exploratory study no power calculation was done.
Normality of data was assessed by visual inspection of histogram
distributions and by using the Shapiro Wilk and Kolmogorov-
Smirnov tests. Data were not normally distributed. Thus, data are
presented using median, interquartile range and percentiles.
Comparisons of outcomes between sexes were made using the
Mann-Whitney U test. Correlations amongst age (as a
continuous variable), frailty index and length of care home
residence (as a continuous variable) were investigated using
Spearmans’s test. Associations between age, frailty index,
length of care home residence and each immune parameter
were investigated using linear regression. Multivariate analysis
using linear regression models was used to examine the
independent influence of age, frailty and length of care home
residence on each immune parameter. All data were log10
transformed prior to conducting these analyses. Data collation
and analysis were performed in SPSS version 22, Microsoft Excel
and PRISM software. In all cases a value for p < 0.05 was taken to




Table 2 shows the characteristics of the subset of participants
studied here compared to those of the entire PRINCESS
cohort; the characteristics are comparable. The age range
of the included care home residents was 65–102 years. They
had a mean age (±SD) of 85.3 (±7.5) yr and had been residing
in the care home for a mean (±SD) of 1.89 (±2.16) yr at
the time of study commencement (Table 2), although it is
not known if they had previously resided in another care
home. There were more women than men (63.4 vs 36.6%).
Over one-third (40.7%) of included participants were
severely frail (category 7) and 42% were moderately or
mildly frail (categories 6 and 5) (Table 2). Age, frailty and
duration of care home residence did not differ between
women and men (data not shown).
Association Amongst Age, Frailty and
Length of Care Home Residence
There was a significant positive correlation between length of care
home residence and frailty index (Spearman’s correlation
coefficient  0.185; p  0.023) as shown in Figure 1A. Age
and frailty index and age and length of care home residence were
not significantly correlated (Figures 1B,C).
Full Blood Count and Immune Parameters
Data for the components of the full blood count were mainly
within the reference range, apart from lymphocyte numbers
(Table 3). Many participants had low blood lymphocyte
numbers, with 31% (n  49) having numbers below the
lower value of the reference range. The percentage of
women and men with lymphocyte numbers below the
lower value of the reference range did not differ. Age,
frailty, and length of care home residence were not
different between those with blood lymphocyte numbers
below or within the reference range. A small proportion of
participants (n  12; 7.6%) had platelet numbers above the
upper value of the reference range. Platelet numbers were
higher in women than men (median (10th and 90th centile)
293 (211, 389) vs 251 (168, 386) 109/L; p  0.039). Data for
immune phenotypes, neutrophil and monocyte phagocytosis,
plasma CRP and immune mediator concentrations, and
concentrations of immune mediators in stimulated whole
blood cultures are shown in Tables 4–7, respectively. There
are no reference values for these immune outcomes, but
Table 4 lists a selection of previously reported vales for
immune phenotypes in older individuals (Seidler et al.,
2010; Tavares et al., 2014; Qin et al., 2016). Participants in
TABLE 1 | Details of immune phenotyping.





T Cells CD45+CD3+ PE-Cy5/AF647 20/5
Helper T cells CD45+CD3+CD4+ PE-Cy5/AF647/AF488 20/5/5
Cytotoxic T cells CD45+CD3+CD8+ PE-Cy5/AF647/BV605 20/5/5
Activated cytotoxic T cells CD45+CD3+CD8+CD25+ PE-Cy5/AF647/BV605/PE 20/5/5/20
Regulatory T cells CD45+CD3+CD4+CD8−CD25HICD127LO PE-Cy5/AF647/AF488/BV605/pE/BV421 20/5/5/5/20/5
Monocytes CD45+CD14+ PE-Cy5/PE-Cy7 20/5
Activated monocytes CD45+CD14+CD80+ PE-Cy5/PE-Cy7/BV421 20/5/20
Activated monocytes CD45+CD14+CD86+ PE-Cy5/PE-Cy7/PE 20/5/20
B Cells CD45+CD3−CD19+ PE-Cy5/AF647/AF488 20/5/5
Activated B cells CD45+CD3−CD19+CD80+ PE-Cy5/AF647/AF488/BV421 20/5/5/20
Activated B cells CD45+CD3−CD19+CD86+ PE-Cy5/AF647/AF488/PE 20/5/5/20
Natural killer cells CD45+CD3−CD16+ PE-Cy5/AF647/BV605 20/5/20
AF, alexa fluor; BV, brilliant violet; Cy5, cyanine 5; PE, phycoerythrin.
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the current study had lower numbers of T lymphocytes and
natural killer cells and a lower ratio of CD4+ to CD8+ T
lymphocytes than reported in these other studies of older
adults. Ten percent of participants had a ratio of CD4+ to
CD8+ T lymphocytes less than 1 (Table 4). The only immune
outcome that differed between sexes was plasma IL-10
concentration, which was higher in men than women
(median (10th and 90th centile) 0.66 (0.25, 3.59) vs 0.56
(0.12, 1.64) pg/ml; p  0.039).
Relationship Between ImmuneMarkers and
Age, Frailty and Length of Care Home
Residence
Univariate Analysis
Associations of each immune marker with age, frailty and length
of care home residence were investigated. In most cases there was
no statistically significant association (Supplementary Tables
S1–S7). Exceptions were:
• Platelet numbers were positively associated with frailty
index (p  0.003).
• Plasma CRP, IL-1ra, sE-selectin, and IP-10 were positively
associated with frailty index (p  0.014, 0.023, 0.015, and
0.016, respectively) (Figure 2).
• PGN-stimulated IL-10 production was inversely associated
with frailty index (p  0.031).
• Plasma sVCAM-1, IP-10 and TNFRII were positively associated
with age (p  0.023, 0.002, and 0.002, respectively) (Figure 3).
TABLE 2 | Characteristics of participants in this study and those of the full PRINCESS cohort at commencement of study and enrollment.
Variable Full PRINCESS cohort Subset participating in this study
n Mean (SD) Median (IQR) Min, max n Mean (SD) Median (IQR) Min, max
Age (yr) 310 85.3 (7.4) 86 (81–91) 65, 102 184 83.1 (15.7) 86 (80–91) 65, 102
Length of care home residence (yr) 307 1.7 (2.4) 1 (0–2) 0, 15 184 1.8 (2.2) 1 (0.4–2.4) 0, 15
Frequency % Frequency %
Sex 310 183
Male 103 33.2 67 36.6
Female 207 66.8 116 63.4
Frailty index 310 150
1 (very fit) 4 1.3 1 0.7
2 (well) 8 2.6 5 3.3
3 (managing well) 19 6.1 13 8.7
4 (vulnerable) 11 3.5 7 4.7
5 (mildly frail) 20 6.5 13 8.7
6 (moderately frail) 84 27.1 50 33.3
7 (severely frail) 158 51.0 61 40.7
8 (very severely frail) 6 1.9 0 0
9 (terminally ill) 0 0 0 0
FIGURE 1 | Relationships between. (A) frailty index and length of care home residence, (B) frailty index and age, and (C) age and length of care home residence.
The relationship between frailty index and length of care home residence was significant (p  0.023).








Number of cells (109/L)
Neutrophils 2.0–7.5 151 4.5 2.90 7.2
Lymphocytes 1.5–5.0 157 1.6 0.9 2.5
Monocytes 0.2–1.0 158 0.6 0.3 0.9
Eosinophils 0.0–0.5 153 0.1 0.1 0.3
Basophils 0.0–0.1 153 0.1 0 0.1
Total
leukocytes
4–11 109 7.4 5.1 10.5
Platelets 140–400 158 268 191 390
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• Plasma MCP-1 was positively associated with length of care
home residence (p  0.012).
Multivariate Analysis
A linear regression model was used to identify the independent
contribution of age, frailty and length of care home residence to the
various immune parameters as dependent variables (Supplementary
Tables S1–S7). Among the parameters included as part of the full
blood count, frailty was a significant predictive factor for platelet
numbers (adjusted coefficient 0.23 (95% CI: 0.08, 0.37), p  0.002;
Supplementary Table S1). Among the immune phenotypes, age was
a significant predictive factor for activated monocytes as determined
by CD86 expression (adjusted coefficient 2.78 (95% CI: 0.87, 4.70),
p  0.005; Supplementary Table S2). Apart from these, none of the
covariates was found to contribute significantly to the individual
components of the full blood count (Supplementary Table S1) or the
immune cell phenotypes (Supplementary Table S2). There were also
no predictive associations between the covariates and neutrophil or
TABLE 4 | Blood immunophenotypes in older people resident in care homes along with a comparison of values from the literature.















T Cells 148 1,249 875 1,726 1,336 (630) 1,846 (505) —
Helper T cells 148 859 304 1,391 780 (436) 699 (281) —
Cytotoxic cells 148 648 402 1,005 417 (313) 448 (235) —
Activated cytotoxic T cells 142 224 126 367 — 191 (115) —
Regulatory T cells 148 40 16 191 — — —
Ratio CD4+:CD8+ 148 1.3 1.0 1.8 1.8 (1.3) 1.5 (1.2) —
Monocytes 148 500 255 820 — — 420 (165–903)
Activated monocytes (CD80+) 148 152 36 379 — — —
Activated monocytes (CD86+) 148 106 20 275 — — —
NK cells 98 81 49 116 — 448 (223) —
B Cells 148 221 102 342 191 (122) 198 (112) —
Activated B cells (CD80+) 148 119 68 213 — — —
Activated B cells (CD86+) 148 118 72 220 — — —
TABLE 5 | Phagocytosis of E. coli by blood neutrophils and monocytes from older people resident in care homes.
Variable n Median 10th percentile 90th percentile
Neutrophils with phagocytic activity (%) 147 83.9 64.6 91.6
Geometric median fluorescence intensity (GMFI) of active neutrophils 142 256.8 158.6 378.5
Monocytes with phagocytic activity (%) 147 29.9 13.6 47.9
Geometric median fluorescence intensity (GMFI) of active monocytes 147 182.1 105.9 295.9
TABLE 6 | Concentrations of CRP and immune mediators in plasma from older
people resident in care homes.
Variable n Median 10th percentile 90th percentile
CRP (mg/L) 85 2.7 0.5 16.3
sICAM-1 (ng/ml) 95 386 208 764
IL-1ra (pg/ml) 95 1,559 705 4,644
sE-selectin (ng/ml) 95 22.8 11.3 39.8
sVCAM-1 (ng/ml) 95 791 432 1,391
MCP-1 (pg/ml) 95 356 165 691
IP-10 (pg/ml) 95 152 75 285
IL-17 A (pg/ml) 95 0.9 0.6 6.9
TNFRII (pg/ml) 95 4,072 2,119 7,963
IL-6 (pg/ml) 96 4.4 1.7 20.4
IL-10 (pg/ml) 96 0.6 0.1 1.8
TNF-α (pg/ml) 96 17.7 9.2 26.4
TABLE 7 | Immune mediator concentrations in stimulated cultures of whole blood
from older people resident in care homes.
Variable n Median 10th percentile 90th percentile
Lipopolysaccharide-stimulated cultures
IL-10 (pg/ml) 86 2,428 473 10,780
TNF-α (pg/ml) 86 13,231 3,358 32,884
IL-6 (ng/ml) 86 47.6 15.7 87.2
IL-12p70 (pg/ml) 86 24.9 11.6 118.7
IL-1β (pg/ml) 86 4,090 1,476 14,588
Peptidoglycan-stimulated cultures
IL-10 (pg/ml) 86 468 90 2049
TNF-α (pg/ml) 86 3,391 564 11,334
IL-6 (ng/ml) 86 42.4 11.9 100.6
IL-12p70 (pg/ml) 86 14.3 5.3 64.0
IL-1β (pg/ml) 86 318 29 1,448
Phytohaemagglutinin-stimulated cultures
IFN-γ (pg/ml) 86 5.2 0.2 55.1
TNF-α (pg/ml) 86 1,846 658 3,472
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monocyte phagocytosis (Supplementary Table S3). For immune
mediators after stimulation of whole blood cultures, the only
predictive association was between frailty and PGN-stimulated IL-
10 (adjusted coefficient −0.79 (95% CI: 1.54, −0.04), p  0.038,
Supplementary Table S5). Frailty index, age and length of care
home residence each independently predicted some plasma
immune mediators (Supplementary Table S4). Age was a
significant predictor of plasma IP-10 (adjusted coefficient
1.77 (95% CI: 0.61, 2.93), p  0.003), TNFRII (adjusted
coefficient 1.76 (95% CI: 0.60, 2.92), p  0.003) and
sVCAM-1 (adjusted coefficient 1.19 (95% CI: 0.13, 2.26),
p  0.029). Frailty index was an independent predictor of CRP
(adjusted coefficient 1.18 (95% CI: 0.34, 2.01), p  0.006), IL-
1ra (adjusted coefficient 0.43 (95% CI: 0.00, 0.87), p  0.050),
sE-selectin (adjusted coefficient 0.35 (95% CI: 0.05, 0.66), p 
0.024) and IP-10 (adjusted coefficient 0.32 (95% CI: 0.32,
FIGURE 2 | Relationships between frailty index and plasma concentration of (A) CRP, (B) IL-1ra, (C) sE-selectin, and (D) IP-10. All were significant.
FIGURE 3 | Relationships between age and plasma concentration of (A) IP-10 and (B) TNF-RII. Both were significant.
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0.64), p  0.042). Lastly, length of care home residence was an
independent predictor of MCP-1 (adjusted coefficient 0.10
(95% CI: 0.01, 0.19), p  0.026).
DISCUSSION
Few studies have described immune parameters in older people
resident in care homes. Here we describe a selection of immune
and inflammatory markers in blood and ex vivo immune cell
functions in a sample of 184 older people resident in care homes
aged 65–102 years and their association with frailty, age and
length of care home residence. Almost a third of the participants
had low total lymphocyte numbers. Moreover, participants had
lower numbers of T lymphocytes and natural killer cells and a
lower ratio of CD4+ to CD8+ T lymphocytes than reported in
other studies of older adults (Tavares et al., 2014; Qin et al., 2016).
These findings are consistent with the hallmarks of
immunosenescence (Boraschi et al., 2013; Pera et al., 2015;
Weyand and Goronzy, 2016) and would indicate an increased
risk of infections and poor vaccination responses (Crétel et al.,
2010; Bektas et al., 2017). Lymphocyte numbers were not
associated with age or frailty. This contrasts with the report of
Collerton et al. (2012) who found an inverse association of
lymphocyte numbers with frailty, assessed using two different
models, in 845 85 years olds in the United Kingdom.
Furthermore, Bernabeu-Wittel et al. (2019) identified that low
lymphocyte numbers were associated with frailty in hospitalized
older people with poly-pathologies; they also identified that frailty
was a risk factor for mortality at 12 months. In another study,
there was an inverse association between frailty score and
lymphocyte count in institutionalized older people, but
lymphocyte count did not predict hospitalisations or mortality,
although frailty did predict mortality (Fernandez-Garrido et al.,
2018). Recently, low lymphocyte counts were shown to associate
with frailty in patients with cardiovascular disease (Bodolea et al.,
2020).
Other associations identified in the current study indicate links
between greater frailty and increased inflammation and between
increasing age and increased inflammation. The association
between frailty and inflammation is consistent with the
proposal that frailty is an inflammatory condition
(Bruunsgaard and Pedersen, 2003; Angulo et al., 2016), while
the associations between age and inflammatory markers or
responses are consistent with the concept of inflammageing
(Breitbart and Stollar, 2000; Ferrucci and Fabbri, 2018).
A proportion of participants (7.6%) had a platelet count above
the upper limit of the reference range. The exact threshold at
which platelet numbers become a marker of chronic
inflammation has not been clearly defined, but high platelet
numbers are related to inflammatory conditions, cancer and
infection as well as endothelial dysfunction (Jones, 2016;
Haynes et al., 2017) and atherosclerotic plaque formation
(Stolla et al., 2016). Moreover, platelet numbers increased
across categories of frailty, findings also confirmed through
modelling, where frailty emerged as a significant independent
predictor of platelet numbers. Recently, Bodolea et al. (2020)
found that platelet numbers associate with frailty in patients with
cardiovascular disease. Fuentes et al. (2017) report that platelet
oxidative stress is a novel marker of cardiovascular risk in frail
older people and Starr and Deary (2011) observed increased
platelet numbers over a time-frame of 8 years in individuals
initially aged over 79 years. The current study did not reveal a
significant association of platelet numbers with age. Nevertheless,
increased platelet numbers could be a marker of mortality risk
through increased frailty. Platelets trigger leukocyte adhesion
which favors their aggregation. The mechanism seems to be
linked to platelet-induced production of adhesion molecules
(Garraud et al., 2012; Jenne et al., 2013).
CD80 and CD86 were used as markers of activated blood
monocytes. The linear regression model showed that age was a
significant independent predictor of CD86+ monocytes over
frailty and length of care home residence. Busse et al.
demonstrated that monocytes expressing CD86 were increased
in elderly individuals (Busse et al., 2015) and concluded this to be
a consequence of immunosenescence/inflammageing, as this trait
appeared in both a cohort of elderly individuals with dementia
and in healthy age-matched controls (Busse et al., 2015).
Phagocytic function has been reported to decline with age
leading to a failure to remove foreign antigenic particles and
autologous senescent cells (Goronzy and Weyand, 2012; Li,
2013). In the current study, phagocytic function of neutrophils
and monocytes was not significantly associated with age, frailty or
length of care home residence. These findings do not confirm
what has been shown by others where phagocytic function,
especially of neutrophils, declined with age (Butcher et al.,
2000; Butcher et al., 2001). However, this may be because the
current study only investigated older participants. A previous
comparison of neutrophil phagocytosis among three age groups
(21–36, 38–56, and 62–83 years) found a significant age-
dependent reduction in the number of phagocytosed E. coli
(Wenisch et al., 2000). Thus, that study investigated a much
wider age range than in the current study. It is possible that
beyond 65 years of age, the alteration in phagocytic activity of
neutrophils and monocytes becomes less dramatic than the
change between young and older or middle-aged and older
individuals.
Previous studies have associated markers of inflammation with
different chronic and age-related conditions (e.g., cardiovascular
disease and dementia (Assar et al., 2016; Calabrese et al., 2018).
Others have reported that age and frailty are factors associated with
inflammatory biomarkers (Bruunsgaard and Pedersen, 2003;
Angulo et al., 2016; Branas et al., 2018). Indeed, researchers
have reported that there is a characteristic “cytokinome”
(Costantini et al., 2010) in older people with physical frailty and
sarcopenia (Marzetti et al., 2019), suggesting IP-10 to be a marker
of frailty and sarcopenia. The current study identified that IP-10
was associated with frailty. In the current study frailty was also an
independent predictor of CRP, IL-1ra and sE-selectin. Previous
studies have shown that aging is associated with increased
concentrations of sICAM-1 and sVCAM-1 (Calder et al., 2017;
Calabrese et al., 2018). The current study found that sVCAM-1
concentration had an association with age, as did IP-10 and
TNFRII. These findings support the idea that inflammatory
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pathways are upregulated in aging and in age-related diseases
(Cardoso et al., 2018).
Beyer et al. suggest that inflammation is related to muscle
wasting, facilitating progression of frailty: in a population of 33
geriatric individuals, those with higher MCP-1 showed a
significantly lower grip strength and lower lean body mass (Beyer
et al., 2012). Animal research has suggested thatMCP-1 is a potential
biomarker of biological aging (Yousefzadeh et al., 2018). However,
one study reported lower plasma MCP-1 in frail compared with
non-frail older care home residents (Seto et al., 2015), while in the
current study frailty was not a predictor of MCP-1 concentration.
Other inflammatory markers where frailty appeared as a
significant contributory factor over age and length of stay at care
home—identified through the regression model—were IL-1ra and
the soluble adhesion molecule sE-selectin. IL-1ra opposes the action
of pro-inflammatory IL-1 and may be released in an effort to
mitigate inflammation. Nevertheless, IL-1ra has been linked as an
independent risk factor of morbidity and mortality in the older
people resident in care homes (Bruunsgaard and Pedersen, 2003).
Upregulation of the expression of adhesionmolecules with frailty has
been reported (Licastro et al., 2005; Jenny, 2012).
Inflammageing, either low grade or chronic, is commonly
linked to morbidity and mortality (Ahmad et al., 2009; Ahmadi-
Abhari et al., 2014). Our findings support an association of
inflammation with frailty in older people resident in care
homes. Inflammageing is a predictor of frailty in elderly
(Zhang et al., 2017). Edvardsson et al. have demonstrated that
inflammatory markers are related to reduced survival in a follow-
up study for one year with frail older people resident in care
homes (Edvardsson et al., 2019).
Experiments to assess cellular responses ex vivo were
performed through whole blood cultures. These experiments
allowed assessment of inflammatory and immune mediator
production via stimulation of toll-like receptor (TLR)2 and
TLR4 with PGN and LPS, respectively, as well as T cell
stimulation with PHA. The activation of TLR2 and TLR4
leads to increased production of multiple cytokines
(Schwandner et al., 1999; Skinner et al., 2005). Findings herein
presented showed that IL-10, TNF-α and IL-1β were potently
induced by LPS in comparison to PGN. LPS induced median
production values 5-fold higher for IL-10, 3.9-fold higher for
TNF-α and almost 12-fold higher for IL-1β when compared with
PGN. Furthermore, a superior production of IL-12p70 was
induced by LPS when compared with PGN, but the difference
was less (two-fold). Lastly, IL-6 was similarly induced by both
PGN and LPS. PHA stimulates T cells. The production of TNF-α
following PHA stimulation was lower than with LPS and PGN.
The potent effects exerted by LPS agree with what has been shown
by others (Andersson et al., 1992). The association of health and
TLR responsiveness, particularly TLR4, in older people resident
in care homes has not been widely explored. McFarlin et al. have
suggested that TLR4 appears to have a role in regulating the
linkage between cytokine production (IL-1β and TNF-α) and
physically active lifestyle regardless of age. In that study, a group
of older (60–80 years) and young (18–30 years) adults were
categorized as “active” or “inactive.” There was significantly
higher production of IL-1β and TNF-α in the inactive group
in both young and older people (McFarlin et al., 2006). McFarlin
et al. (2006) also reported lower expression of TLR4 in the active
group. Similar observations were reported in a group of older
women exposed to regular training (McFarlin et al., 2004).
Current findings certainly suggest an active TLR4 pathway in
the older people resident in care homes according to the cytokine
production detected in the cultures following LPS stimulation. A
predisposition to active responses of innate immune cells via
TLR4, and perhaps other pattern recognition receptors, may be
one reason for higher circulating concentrations of inflammatory
cytokines in older people, one of the hallmarks of inflammageing.
IL-10 induced by PGN was significantly inversely associated
with frailty. IL-10 is an anti-inflammatory cytokine that
counterbalances pro-inflammatory responses (Iyer and Cheng,
2012). The older people resident in care homes appeared to show
an imbalance in IL-10 and TNF-α.
Our findings may be compared with those of Collerton et al.
(2012) who measured a range of immune and inflammatory
parameters in 845 85 years olds in the United Kingdom and
related these to frailty assessed with two different models. As
mentioned earlier, that study reported an inverse association
between frailty and lymphocyte numbers which was not observed
in the current study. This may represent differences in the
characteristics of the participants included in the two studies (all
were resident in care homes in the current study whereas this was
not the case in Collerton et al. (2012)); age range was 66–102 years in
the current study but all participants were aged 85 years in Collerton
et al. (2012) or the smaller sample size of the current study. Collerton
et al. (2012) also reported positive associations of frailty with total
leukocyte and neutrophil counts, which we did not observe.
Collerton et al. (2012) reported a positive association between
frailty and CRP concentrations, as observed in the current study.
They also identified a lack of association of frailty with monocyte,
basophil, and eosinophil counts, ratio of CD4+ to CD8+
lymphocytes, and LPS-stimulated TNF-α and IL-6 production;
our observations are consistent with this. Collerton et al. (2012)
did not report platelet numbers or plasma concentrations of
inflammatory mediators, which were associated with frailty in the
current study.
The current study has several strengths. There were few
restrictions on participant inclusion. A broad range of immune
and inflammatory outcomes were measured, representing several
different components of the immune system; these included static
measures in blood (full blood count, immune phenotypes, plasma
mediators, CRP) as well cell responses after challenge (phagocytosis,
blood culture responses to LPS, PGN, and PHA) and components of
innate (phagocytosis, blood culture responses to LPS and PGN) and
acquired immunity (blood culture responses to PHA). Finally, linear
regression modelling was used to identify independent effects of age,
frailty, and time of care home residence on the outcomes reported.
However, the study also has some limitations. Firstly, not all immune
outcomes were available for all 184 participants; this is mainly
because some blood samples did not arrive at the laboratory
within a predetermined time to assure the viability of the
immune assay (Castro-Herrera et al., 2018). Secondly, the
samples were from participants in a randomized controlled trial
(Owen-Jones et al., 2019; Butler et al., 2020) and this required
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exclusion of some of the care home residents; thus the findings are
not generalisable to all care home residents. Thirdly, we did not
collect data on co-morbidities (other than frailty index) or
medication use, which might be relevant to immune and
inflammatory biomarkers. Finally, since the study was exploratory
no power calculationwas done, and so non-significant findingsmust
be interpreted with caution, and significant findings interpreted
cautiously since we did not correct for the multiple statistical
comparisons performed.
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